secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001493152-25-012479
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025
--------------------------------------------------------------------------------

- CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.
- Breen continues as Executive Chairman and CEO; may perform duties from UK or elsewhere outside US.
- Amendment No. 3 signed August 26, 2025, retroactively effective April 29, 2025.
- No other changes to Breen's compensation or benefits under the existing employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315225012479/0001493152-25-012479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315225012479/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer